250 related articles for article (PubMed ID: 23529793)
1. RANKL subcellular trafficking and regulatory mechanisms in osteocytes.
Honma M; Ikebuchi Y; Kariya Y; Hayashi M; Hayashi N; Aoki S; Suzuki H
J Bone Miner Res; 2013 Sep; 28(9):1936-49. PubMed ID: 23529793
[TBL] [Abstract][Full Text] [Related]
2. MLO-Y4 osteocyte-like cells support osteoclast formation and activation.
Zhao S; Zhang YK; Harris S; Ahuja SS; Bonewald LF
J Bone Miner Res; 2002 Nov; 17(11):2068-79. PubMed ID: 12412815
[TBL] [Abstract][Full Text] [Related]
3. Regulatory mechanisms of RANKL presentation to osteoclast precursors.
Honma M; Ikebuchi Y; Kariya Y; Suzuki H
Curr Osteoporos Rep; 2014 Mar; 12(1):115-20. PubMed ID: 24477414
[TBL] [Abstract][Full Text] [Related]
4. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
[TBL] [Abstract][Full Text] [Related]
5. Function of OPG as a traffic regulator for RANKL is crucial for controlled osteoclastogenesis.
Aoki S; Honma M; Kariya Y; Nakamichi Y; Ninomiya T; Takahashi N; Udagawa N; Suzuki H
J Bone Miner Res; 2010 Sep; 25(9):1907-21. PubMed ID: 20560139
[TBL] [Abstract][Full Text] [Related]
6. Osteocytes produce interferon-β as a negative regulator of osteoclastogenesis.
Hayashida C; Ito J; Nakayachi M; Okayasu M; Ohyama Y; Hakeda Y; Sato T
J Biol Chem; 2014 Apr; 289(16):11545-11555. PubMed ID: 24610813
[TBL] [Abstract][Full Text] [Related]
7. IL-6 Enhances Osteocyte-Mediated Osteoclastogenesis by Promoting JAK2 and RANKL Activity In Vitro.
Wu Q; Zhou X; Huang D; Ji Y; Kang F
Cell Physiol Biochem; 2017; 41(4):1360-1369. PubMed ID: 28278513
[TBL] [Abstract][Full Text] [Related]
8. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
9. Apoptotic osteocytes regulate osteoclast precursor recruitment and differentiation in vitro.
Al-Dujaili SA; Lau E; Al-Dujaili H; Tsang K; Guenther A; You L
J Cell Biochem; 2011 Sep; 112(9):2412-23. PubMed ID: 21538477
[TBL] [Abstract][Full Text] [Related]
10. High mobility group box 1 protein regulates osteoclastogenesis through direct actions on osteocytes and osteoclasts in vitro.
Davis HM; Valdez S; Gomez L; Malicky P; White FA; Subler MA; Windle JJ; Bidwell JP; Bruzzaniti A; Plotkin LI
J Cell Biochem; 2019 Oct; 120(10):16741-16749. PubMed ID: 31106449
[TBL] [Abstract][Full Text] [Related]
11. Iron Overload-Induced Osteocyte Apoptosis Stimulates Osteoclast Differentiation Through Increasing Osteocytic RANKL Production In Vitro.
Yang J; Dong D; Luo X; Zhou J; Shang P; Zhang H
Calcif Tissue Int; 2020 Nov; 107(5):499-509. PubMed ID: 32995951
[TBL] [Abstract][Full Text] [Related]
12. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y
Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790
[TBL] [Abstract][Full Text] [Related]
13. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
Kondo H; Guo J; Bringhurst FR
J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
[TBL] [Abstract][Full Text] [Related]
14. Unfractionated Heparin Promotes Osteoclast Formation in Vitro by Inhibiting Osteoprotegerin Activity.
Li B; Lu D; Chen Y; Zhao M; Zuo L
Int J Mol Sci; 2016 Apr; 17(4):. PubMed ID: 27110777
[TBL] [Abstract][Full Text] [Related]
15. Cortical bone loss caused by glucocorticoid excess requires RANKL production by osteocytes and is associated with reduced OPG expression in mice.
Piemontese M; Xiong J; Fujiwara Y; Thostenson JD; O'Brien CA
Am J Physiol Endocrinol Metab; 2016 Sep; 311(3):E587-93. PubMed ID: 27460899
[TBL] [Abstract][Full Text] [Related]
16. Soluble glucocorticoid-induced tumor necrosis factor receptor stimulates osteoclastogenesis by down-regulation of osteoprotegerin in bone marrow stromal cells.
Shin HH; Kim SJ; Kang SY; Lee DS; Choi HS
Bone; 2006 Oct; 39(4):716-23. PubMed ID: 16750437
[TBL] [Abstract][Full Text] [Related]
17. Vps33a mediates RANKL storage in secretory lysosomes in osteoblastic cells.
Kariya Y; Honma M; Aoki S; Chiba A; Suzuki H
J Bone Miner Res; 2009 Oct; 24(10):1741-52. PubMed ID: 19419298
[TBL] [Abstract][Full Text] [Related]
18. Effect of fluoride on osteocyte-driven osteoclastic differentiation.
Jiang N; Guo F; Xu W; Zhang Z; Jin H; Shi L; Zhang X; Gao J; Xu H
Toxicology; 2020 Apr; 436():152429. PubMed ID: 32156525
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide regulates osteocytes fate and related osteoclastogenesis via IL-1β/NF-κB/RANKL signaling.
Qu X; Mei J; Yu Z; Zhai Z; Qiao H; Dai K
Biochem Biophys Res Commun; 2018 Jun; 501(2):547-555. PubMed ID: 29746861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
